Resistant hypertension

Blood Pressure

Volumn 14, Issue SUPPL. 2, 2005, Pages 42-45

  Tykarski, Andrzej ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b NONE   (Poland)

Author keywords

Compliance; Refractory hypertension; Resistant hypertension; Treatment of hypertension

Indexed keywords

ANABOLIC AGENT; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; BRONCHODILATING AGENT; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PSYCHOTROPIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DOCTOR PATIENT RELATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MEDICATION ERROR; METABOLIC SYNDROME X; OBESITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; WHITE COAT HYPERTENSION; DRUG RESISTANCE; PATHOPHYSIOLOGY; PHYSICIAN; REVIEW;

ALCOHOL-RELATED DISORDERS; ANTIHYPERTENSIVE AGENTS; DRUG RESISTANCE; HUMANS; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; SMOKING; PATIENT COMPLIANCE; PHYSICIANS;

EID: 31744451508     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08038020500428989     Document Type: Article

References (9)

1. Alderman, M. H. and Budner, N. and Cohen, H. and Lamport, B. and Ooi, W. L. (1988) Prevalance of drug resistant hypertension. Hypertension, 11((3 Pt 2)), pp. II71 - II75.
2. Yakovlevitch, M. and Black, H. R. (1991) Resistant hypertension in a tertiary care clinic. Arch Intern Med, 151, pp. 1786 - 1792.
3. Hansson, L. and Zanchetti, A. and Carruthers, S. G. and Dahlof, B. and Elmfeldt, D. and Julius, S. and (1998) Effects of intensive blood pressure reduction and low dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351, pp. 1755 - 1762.
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA, 288, pp. 2981 - 2997.
5. Staessen, J. A. and Fagard, R. and Thijs, L. and Celis, H. and Arabidze, G. G. and Birkenhagen, W. H. and (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension-Europe (Syst-Eur) Trial Investigators. Lancet, 350, pp. 757 - 764.
6. Dahlof, B. and Devereux, R. and Kjeldsen, S. E. and Julius, S. and Beevers, G. and de Faire, U. and (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359, pp. 995 - 1003.
7. Ruud, P. (1995) Clinicians and patients with hypertension: Unsettled issues about compliance. Am Heart J, 130, pp. 572 - 589.
8. Grodzicki, T. and Gasowski, J. and Rywik, S. and Gryglewska, B. and Broda, G. (2003) Risk of uncontrolled hypertension according to current treatment regimen. J Hypertens, 21 Suppl 4, pp. S285.
9. Ouzan, J. and Perault, C. and Lincoff, A. M. and Carre, E. and Mertes, M. (2002) The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens, 15, pp. 333 - 339.